Adherence and persistence to novel glucose-lowering medications in persons with type 2 diabetes mellitus undergoing routine care
Authors' conclusion
We report adherence and persistence to SGLT2i, GLP1-RA and DPP4i in routine care, and identify prognostic factors that could inform implementation interventions to improve uptake of these important therapies.
Study context
- Population
- New-users of SGLT2i, GLP-1 RA and/or DPP-4i with T2D in routine care, Stockholm region, Sweden, 2015–2020
- Participants
- 10,743 / 10,315 / 9,488
- Exposure
- SGLT2i vs GLP-1 RA vs DPP-4i
- SGLT2in = 10,743
- GLP1-RAn = 10,315
- DPP4in = 9,488reference
- Outcome
- Adherence (≥80 % of days covered by an active supply)
- Follow-up
- 2.8 years median
Methodological detailsnew-user design, routine care data, Stockholm region, Sweden
- New-user design
- Routine care data, Stockholm region, Sweden
Main finding
As reported in the abstract
Adherence (≥80 % of days covered)
SGLT2i vs DPP4i: P < 0.001 · GLP1-RA vs DPP4i: P < 0.001
Observational data: associations, not effects.
Further findings
Persistence (no treatment gap ≥ 60 days) · 2.8 years median follow-up — SGLT2i vs DPP4i · higher with SGLT2i
P < 0.001
| Outcome | P value |
|---|---|
| Persistence (no treatment gap ≥ 60 days) · 2.8 years median follow-upGLP1-RA vs DPP4i · higher with GLP1-RA | P < 0.001 |
Predictors of adherence
- Better overall adherence among users who were older, had a history of high blood pressure, used more non-diabetic medications, had lower HbA1c, better kidney function, and completed secondary schooling or university
- Women had worse adherence to SGLT2i and GLP1-RA than DPP4i
Parts of this Brief are withheld: the automatic checks could not confirm them against the abstract.
Original publication
Adherence and persistence to novel glucose-lowering medications in persons with type 2 diabetes mellitus undergoing routine care. Diabetes Res Clin Pract. Published 13 June 2024. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →